Sexual stimulant supplement recall
This article was originally published in The Tan Sheet
Executive Summary
Roughly 24 mil. pills contaminated with Rx erectile dysfunction drug ingredient tadalafil, the active in Eli Lilly's Cialis, were destroyed Dec. 19 under FDA's oversight, marketers Hi-Tech Pharmaceuticals and National Urological Group report. Twenty-four lots containing 1 mil. pills each were recalled in August. FDA released a consumer warning in June alerting the public to the contamination. Manufactured by NVE Pharmaceuticals, recalled products include Stamina-Rx and Stamina-Rx for Women, Uroprin, Sigra, Spontane-ES and Vigor-Rx (1"The Tan Sheet" June 23, 2003, In Brief)...
You may also be interested in...
FDA advisory on contaminated supplements
FDA warns consumers not to purchase or consume several dietary supplements manufactured by NVE Pharmaceuticals and distributed by Norcross, Ga.-based Hi-Tech due to contamination with Rx erectile dysfunction ingredient tadalafil (Eli Lilly's Cialis). In a June 20 release, FDA notes Sigra, Stamina Rx, Stamina Rx for Women, Y-Y, Spontane ES and Uroprin, which claim to increase stamina and performance, actually pose health risks because interaction between certain Rx drugs and tadalafil "may cause a drastic lowering of blood pressure." This is of particular concern since erectile dysfunction "is often a common problem in people with diabetes, hypertension," ischemic heart disease and who smoke, FDA says. Agency notes its Office of Criminal Investigations executed concurrent federal search warrants in Georgia and New Jersey, where NVE is based, after discovering the supplements...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.